Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...

In heart failure, the heart can no longer supply the body with enough blood. The condition often develops over many years, ...

In May 2025, the world celebrated the success of KJ, an infant who was treated with the world’s first personalized CRISPR gene editing therapy. KJ was born with severe carbamoyl phosphate synthetase 1 ...

Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing "copilot" ...

In the first of a new series of GEN Keynote Webinars, Professor Rodolphe Barrangou, PhD (North Carolina State; EIC, The CRISPR Journal) offers a front-row perspective of the CRISPR revolution, the ...

CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost ...

There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...

Despite a lackluster launch, CASGEVY has significant potential in international markets, bolstering CRISPR's long-term value. Upcoming milestones and updates on CRISPR Therapeutics is currently ...

Shares of CRISPR Therapeutics have struggled amid less-than-stellar sales of its Casgevy therapy. The company's gene-editing biotechnology holds much promise but still faces significant uncertainties.